SLC31A1 and neoplasm: There was no significant difference in the expression levels of anti-COPT1 autoantibodies between early and advanced NSCLC (Supplementary Figures 1B, C), indicating that the anti-COPT1 autoantibodies did not increase with tumor stage progression.